tirzepatide cardiovascular outcomes study trial results july 2025 Achieving BMI <25 kg/m2 was associated with reduced Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with

When clients ask me whether they should use a GLP-1 medication to lose the last 5 to 10 pounds, I come back to the same question: To what end

N c xem nh l chic nam chm ht ly, bt gi cc gc t do, kim loi nng v cht c t c hp th mi ngy qua da, phi, nc ung, thc phm bn

Creating a support system of healthcare providers, family, or weight loss groups can give you the motivation and support you need to cross that finish line

It is the most frequently reported side effect of tirzepatide, affecting roughly 15 to 30 percent of patients depending on the dose

Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN3): a 56-week, open-label, randomized clinical trial